NASDAQ
18.11.25 | 21:59
14,980 US-Dollar
+3,96 % +0,570
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Phathom Pharmaceuticals startet Phase-2-Studie mit VOQUEZNA bei eosinophiler Ösophagitis | 3 | Investing.com Deutsch | ||
| 30.10. | Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth | 1 | Seeking Alpha | ||
| 30.10. | Phathom Pharmaceuticals stock price target raised to $20 by Guggenheim | 2 | Investing.com | ||
| 30.10. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.10. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 25.10. | Phathom: Neue Studiendaten belegen Wirksamkeit von Vonoprazan bei nächtlichen Reflux-Symptomen | 3 | Investing.com Deutsch | ||
| 25.10. | Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease | 2 | GlobeNewswire (USA) | ||
| 23.10. | Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting | 4 | GlobeNewswire (USA) | ||
| 20.10. | Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 | 4 | GlobeNewswire (USA) | ||
| 15.10. | Phathom stock remains Overweight at Cantor Fitzgerald on sales strategy shift | 1 | Investing.com | ||
| 15.10. | Strategiewechsel im Vertrieb: Cantor Fitzgerald stuft Phathom-Aktie weiter mit "Overweight" ein | 4 | Investing.com Deutsch | ||
| 09.10. | Cantor Fitzgerald reiterates Phathom stock as top pick with $29 price target | 2 | Investing.com | ||
| 09.10. | Cantor Fitzgerald bestätigt Phathom als Top-Pick mit Kursziel von 29 US-Dollar | 4 | Investing.com Deutsch | ||
| 06.10. | Phathom Pharmaceuticals Appoints Sanjeev Narula As Chief Financial And Business Officer | 2 | RTTNews | ||
| 06.10. | Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer | 1 | Investing.com | ||
| 06.10. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | Phathom Pharmaceuticals clarifies no reduction in Frazier ownership | 2 | Investing.com | ||
| 20.08. | Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing | 1 | GlobeNewswire (USA) | ||
| 08.08. | Phathom projects $165M-$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth | 2 | Seeking Alpha | ||
| 07.08. | Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat | 1 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SAREPTA THERAPEUTICS | 15,220 | +1,13 % | FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ADAPTIMMUNE THERAPEUTICS | 0,052 | +51,47 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| NUVALENT | 104,24 | -3,49 % | Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 20,190 | 0,00 % | Morning Market Movers: Olema Pharmaceuticals, LifeMD, Alpha Technology Group, Intellinetics See Big Swings | HELSINKI (dpa-AFX) - At 8:10 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 37,755 | -1,04 % | AIM WINNERS & LOSERS: CelLBxHealth rises on Qiagen deal | ||
| ARVINAS | 13,000 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| DISC MEDICINE | 89,74 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,84 | +0,23 % | TD Cowen reiterates Hold rating on Avidity Biosciences stock at $74 | ||
| TANGO THERAPEUTICS | 8,000 | +0,25 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights | - Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months- - Combination studies with RAS(ON) inhibitors ongoing, data anticipated... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 43,460 | -1,81 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| EVOTEC | 5,202 | -0,23 % | EQS-News: Evotec SE: Evotec erhält Meilenstein-Zahlung von Bristol Myers Squibb nach Zulassung eines IND-Antrags in der strategischen Partnerschaft im Bereich Protein Degradation | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec erhält Meilenstein-Zahlung von Bristol Myers Squibb nach Zulassung eines IND-Antrags in der strategischen Partnerschaft im... ► Artikel lesen | |
| BIONTECH | 88,55 | 0,00 % | JEFFERIES stuft Biontech auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Biontech mit einem Kursziel von 151 US-Dollar auf "Buy" belassen. Auf seinem Forschungs- und Entwicklungstag habe der Mainzer Antikörperspezialist... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,280 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,385 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report |
Das Unternehmen PHATHOM PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,570 (+3,96 %) liegt der Kurs bei 14,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.